Media

  • CPHI North America was a success for Ami Lifesciences Pvt Ltd. We appreciate our clients and guests stopping

    April 25 to 27, 2023.

    read more

  • We are exhibiting at CPHI North America, and you are welcome to visit the Ami Lifesciences

    April 25 to 27, 2023.

    read more

  • We are pleased to inform that we are now EcoVadis Certified, the most widely recognized international

    20 April 2023

    read more

  • We are excited to be at CPhI Japan (19-21 April 2023). It will be a pleasure to meet our customers

    10 April 2023

    read more

  • We will be exhibiting at the CPHI North America Exhibition in Pennsylvania from April 25th to 27th, 2023.

    10 April 2023

    read more

  • The USDMF for Empagliflozin API submitted to the USFDA. Our expert team created and scaled up a lean process to assist our formulation partners

    27 Mar 2023

  • Ami Lifesciences had a very successful DCAT Week, with significant customer meetings and anticipating an incredible path forward.

    27 Mar 2023

  • We are pleased to inform you that the USDMF for Edoxaban API has been submitted to the USFDA. Based on our process expertise

    27 Mar 2023

    read more

  • Mr Varad Nabar, AVP Marketing, will attend DCAT (Drug, Chemical & Associated Technologies Association) Week 2023 in New York

    20 - 23 Mar 2023

    read more

  • The DCAT (Drug, Chemical & Associated Technologies Association) week is approaching; come meet us and learn more about Ami Lifesciences

    20 - 23 Mar 2023

    read more

  • Our CEO, Amit Kaptain, will be in New York from March 20th to 23rd for DCAT (Drug, Chemical & Associated Technologies Association) Week 2023.

    20 - 23 Mar 2023

    read more

  • It gives us great pleasure to announce that the USDMF for Sacubitril Sodium has been submitted to the USFDA. With an innovative development strategy, our team of experts

    20 Mar 2023

    read more

  • Our innovation efforts have been validated today when our R&D team received Excellence in Research and Development" award.

    20 Mar 2023

    read more

  • We are pleased to inform you that Sacubitril Valsartan's USDMF has been successfully submitted to the USFDA. Our process experts developed Sacubitril Valsartan

    09 Mar 2023

    read more

  • We are pleased to announce that the USDMF for Desvenlafaxine Succinate has been submitted to the USFDA.

    08 Mar 2023

    read more

  • We are glad to share that the US DMF for Sevelamer Hydrochloride was successfully submitted to the USFDA. We have a distinctive advantage

    02 Mar 2023

    read more

  • We are happy to announce our USDMF filing of Dapagliflozin Amorphous to the USFDA.

    02 Mar 2023

    read more

  • We are extremely happy to share the successful filling of Febuxostat USDMF with the USFDA.

    18 Feb 2023

    read more

  • We are happy to share that the US DMF for Sevelamer Carbonate was successfully submitted to the USFDA.

    17 Feb 2023

    read more

  • We are delighted to announce that the USDMF for Tadalafil was successfully submitted to the USFDA.

    17 Feb 2023

    read more

  • We'll be at DCAT (Drug, Chemical & Associated Technologies Association) 2023

    17 Feb 2023

    read more